Aspect Biosystems receives funding for cellular medicine project
Aspect Biosystems has secured a C$79m($56.6m) investment from the Government of Canada to support a C$280m multi-year project aimed at …
Post
-
-
MSD secures EC clearance for Keytruda combination therapy for ovarian cancer
Merck (MSD) has received the European Commission (EC) approval for Keytruda (pembrolizumab) along with paclitaxel, with or without bevacizumab, as …
-
HNSCC market is expected to reach to $4.5bn across 8MM by 2034
GlobalData anticipates notable growth in the head and neck squamous cell carcinoma (HNSCC) therapeutics market across the eight major markets …
-
ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH
At the American College of Cardiology (ACC) Annual Scientific Session & Expo 2026, a systematic review and meta-analysis of sotatercept in pulmonary …
-
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
On 28 March, at the American College of Cardiology (ACC) 75th Annual Scientific Session & Expo in New Orleans, Louisiana, …
-
Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry
The US Food and Drug Administration (FDA) has approved Eli Lilly’s orforglipron pill for weight loss, ending Novo Nordisk’s first …
-
Merck KGaA acquires JSR chromatography business
Germany-based Merck KGaA (Merck) has completed its previously announced acquisition of the chromatography business of JSR Life Sciences. This follows the …
-
Biocytogen and Sihuan partner to advance new therapeutics for weight loss
Biocytogen has entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas, including weight loss. Under …
-
ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D
Type 2 diabetes (T2D) and heart health have a complex and dependent relationship. New data presented at ACC 2026 suggests …
-
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout
Biogen has forged a $5.6bn deal to acquire immunology and rare disease specialist Apellis Pharmaceuticals – marking another M&A milestone …
-
Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa
Eli Lilly will acquire neuroscience specialist Centessa Pharmaceuticals in a deal worth up to $7.8bn, solidifying the drugmaker’s status as …
-
Telomir seeks FDA approval for Telomir-1 to treat breast cancer
Telomir Pharmaceuticals has submitted an investigational new drug application to the US Food and Drug Administration for Telomir-1 (Telomir-Zn), its …
-
ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose
At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, the phase II CADENCE trial reported results …
-
ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit
At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, the KARDINAL phase II trial assessed tonlamarsen, …
-
Symeres and Ambagon collaborate for colorectal cancer molecules
Symeres has entered a collaboration with Ambagon Therapeutics on molecular glue research in colorectal cancer, aiming to address diseases considered …
